Replies to post #302211 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

A little sheepishly I admit I do not know. Bad for me as I was big in SGEN years ago and that was pure blood cancers.

In general they measure the amount of cancerous cells in the bone. OK, that definitiion sucks.

Had I known then what I know now about biotech I would have clearly understood what they were measuring so they could not scam me.

I trust my mother, and that is it. :-)

[longfellow95]

'Remission rate' apparently.

“Kymriah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER). “Not only does Kymriah provide these patients with a new treatment option where very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials.”

The safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. The overall remission rate within three months of treatment was 83 percent.

“Kymriah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER). “Not only does Kymriah provide these patients with a new treatment option where very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials.”

https://www.drugs.com/newdrugs/fda-approves-kymriah-tisagenlecleucel-car-t-gene-therapy-acute-lymphoblastic-leukemia-4588.html

Yescarta also 'remission rate'.
https://www.drugs.com/newdrugs/fda-approves-kymriah-tisagenlecleucel-car-t-gene-therapy-acute-lymphoblastic-leukemia-4588.html

No telling how long the remission lasted.